Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1028321

	registered interest
	date	18/12/2018
	answering body	Department for Education
	answering dept id	60
	answering dept short name	Education
	answering dept sort name	Education
	hansard heading	Music: Qualifications
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the consequences for mutual recognition of music qualifications if the UK leaves the EU without a deal.
	tabling member printed	Lord Clement-Jones
	uin	HL12395
	answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>Music qualifications are not included in the EU Mutual Recognition of Professional Qualifications Directive. The EU only has supporting competence in education and there is no EU law on the recognition of academic qualifications.</p><p> </p> answering member printed Viscount Younger of Leckie question first answered 20/12/2018 17:06:10 answering member 4169 label Biography information for Viscount Younger of Leckie
	tabling member	3396 label Biography information for Lord Clement-Jones

389137

	registered interest
	date	13/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government why they are reviewing the Cancer Drugs Fund list, given the January review; and whether any assessment has been made of the impact on patients of the frequency with which medicines on the Cancer Drugs Fund list are reviewed.
	tabling member printed	Lord Clement-Jones
	uin	HL1323
	answer	answer is ministerial correction date of answer 22/07/2015 answer text <p>The criteria and scoring system for reviewing the current listed drugs within the Cancer Drugs Fund (CDF) is outlined in the published CDF Standard Operating Procedure which is available at: www.england.nhs.uk/ourwork/pe/cdf/. These state that:</p><p> </p><p> </p><p> </p><p>“Decisions will be based on the National Cancer Drugs Fund Prioritisation Tool in conjunction with an assessment of median drug cost per patient. This evaluation will be completed for each drug/indication under consideration and will result in an overall score based on a number of factors, including:</p><p> </p><p>o evidence of clinical benefit e.g. progression free survival (PFS) and overall survival (OS)</p><p> </p><p>o quality of life (QOL)</p><p> </p><p>o toxicity</p><p> </p><p>o unmet need</p><p> </p><p>o median drug cost per patient</p><p> </p><p> </p><p> </p><p>Drugs on the National CDF List will be subject to an affordability test within the overall CDF budget, being added or removed according to their relative aggregate score using the National Cancer Drugs Fund Prioritisation Tool of clinical benefit in conjunction with the assessment of drug cost per patient. Drugs whose aggregate score is below the threshold applicable at the time will not be added/will be removed from the National CDF List.”</p><p> </p><p> </p><p> </p><p>A copy is attached.</p><p> </p><p> </p><p> </p><p>NHS England has advised that the Fund is re-prioritised on a regular basis so that the resources available are used to the best benefit of patients.</p><p> </p><p> </p><p> </p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL1322 question first answered 22/07/2015 16:36:50 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name HL1322 HL1323 CDF SOP.pdf title Cancer Drug Fund SOP
	tabling member	3396 label Biography information for Lord Clement-Jones

453538

	registered interest
	date	22/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how many cancer medicines launched since June 2015 are available via the Cancer Drugs Fund.
	tabling member printed	Lord Clement-Jones
	uin	HL6240
	answer	answer is ministerial correction date of answer 03/03/2016 answer text <p>No new cancer medicines have been added to the national Cancer Drugs Fund (CDF) list since June 2015. As part of its work to reprioritise the Fund in 2015-16, NHS England took the decision not to consider new drugs for inclusion on the national CDF list.</p><p> </p><p>NHS England and the National Institute for Health and Care Excellence (NICE) recently consulted on draft proposals for the future direction of the Fund. The consultation outlines a new system, fully integrated into the NICE appraisal process, where the CDF becomes a transitional fund – with clear criteria for entry and exit.</p><p> </p><p>Clinicians continue to be able to apply for cancer drugs not on the national CDF list through the Individual Cancer Drugs Funding Request procedure.</p> answering member printed Lord Prior of Brampton question first answered 03/03/2016 12:45:59 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3396 label Biography information for Lord Clement-Jones

453539

	registered interest
	date	22/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they have had discussions with NHS England and the National Institute for Health and Care Excellence about whether new medicines not accessible through the Cancer Drugs Fund since June 2015 will be prioritised for early review under the proposed new terms of that Fund.
	tabling member printed	Lord Clement-Jones
	uin	HL6241
	answer	answer is ministerial correction date of answer 03/03/2016 answer text <p>The Department has had regular discussions with the National Institute for Health and Care Excellence and NHS England about the future operation of the Cancer Drugs Fund, including arrangements for the assessment of cancer drugs that are not currently available through the Fund.</p> answering member printed Lord Prior of Brampton question first answered 03/03/2016 12:46:54 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3396 label Biography information for Lord Clement-Jones

453540

	registered interest
	date	22/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the impact on patients of the pause in listing new drugs accessible through the Cancer Drugs Fund introduced in June 2015.
	tabling member printed	Lord Clement-Jones
	uin	HL6242
	answer	answer is ministerial correction date of answer 03/03/2016 answer text <p>We have made no such assessment.</p><p> </p><p>As part of its work to reprioritise the Cancer Drugs Fund (CDF) in 2015-16, NHS England took the decision not to consider new drugs for inclusion on the national CDF list.</p><p> </p><p>NHS England and the National Institute for Health and Care Excellence (NICE) recently consulted on draft proposals for the future direction of the Fund. The consultation outlined a new system, fully integrated into the NICE appraisal process, where the CDF becomes a transitional fund – with clear criteria for entry and exit.</p><p> </p><p>Clinicians continue to be able to apply for cancer drugs not on the national CDF list through the Individual Cancer Drugs Funding Request procedure.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 03/03/2016 12:43:57 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3396 label Biography information for Lord Clement-Jones

453541

	registered interest
	date	22/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of how many more cancer medicines will be available to patients as a result of the proposals for a revised Cancer Drugs Fund to be effective from 1 April.
	tabling member printed	Lord Clement-Jones
	uin	HL6243
	answer	answer is ministerial correction date of answer 03/03/2016 answer text <p>We have made no such assessment.</p><p> </p><p>NHS England and the National Institute for Health and Care Excellence (NICE) recently consulted on draft proposals for the future direction of the Cancer Drugs Fund (CDF). The consultation outlines a new system, fully integrated into the NICE appraisal process, where the CDF becomes a transitional fund – with clear criteria for entry and exit. The consultation closed on 11 February 2016.</p><p> </p><p>NHS England has advised that the operational detail of the new scheme will be developed over the coming months, informed by detailed analysis and consideration of the consultation responses received. A new Standard Operating Procedure for the CDF will be published by June 2016. Any changes to the list of available treatments through the Fund as a result of the changes in model will be published in due course.</p><p> </p><p>NHS England has advised that it is optimistic that a greater number of cancer drugs will be funded from baseline commissioning in the future as a consequence of more appropriate pricing arrangements proposed by pharmaceutical manufacturers and the new CDF being able to address issues as to longer term patient outcomes in order to give such drugs the chance of re-appraisal by NICE with greater certainty as to clinical and cost effectiveness.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL6244 question first answered 03/03/2016 13:17:44 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3396 label Biography information for Lord Clement-Jones

453542

	registered interest
	date	22/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how many patients they expect to benefit from the latest cancer medicines as a result of the proposals for a revised Cancer Drugs Fund to be effective from 1 April.
	tabling member printed	Lord Clement-Jones
	uin	HL6244
	answer	answer is ministerial correction date of answer 03/03/2016 answer text <p>We have made no such assessment.</p><p> </p><p>NHS England and the National Institute for Health and Care Excellence (NICE) recently consulted on draft proposals for the future direction of the Cancer Drugs Fund (CDF). The consultation outlines a new system, fully integrated into the NICE appraisal process, where the CDF becomes a transitional fund – with clear criteria for entry and exit. The consultation closed on 11 February 2016.</p><p> </p><p>NHS England has advised that the operational detail of the new scheme will be developed over the coming months, informed by detailed analysis and consideration of the consultation responses received. A new Standard Operating Procedure for the CDF will be published by June 2016. Any changes to the list of available treatments through the Fund as a result of the changes in model will be published in due course.</p><p> </p><p>NHS England has advised that it is optimistic that a greater number of cancer drugs will be funded from baseline commissioning in the future as a consequence of more appropriate pricing arrangements proposed by pharmaceutical manufacturers and the new CDF being able to address issues as to longer term patient outcomes in order to give such drugs the chance of re-appraisal by NICE with greater certainty as to clinical and cost effectiveness.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL6243 question first answered 03/03/2016 13:17:44 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3396 label Biography information for Lord Clement-Jones

454672

	registered interest
	date	24/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when they expect a reimbursement decision on each of the drugs launched since June 2015 that were affected by the pause in listing new drugs on the Cancer Drugs Fund list.
	tabling member printed	Lord Clement-Jones
	uin	HL6422
	answer	answer is ministerial correction date of answer 07/03/2016 answer text <p>Since June 2015, the National Institute for Health and Care Excellence (NICE) has published final technology appraisal guidance on the cancer drugs/indications listed in the following table.</p><p> </p><table><tbody><tr><td><p>Topic title</p></td><td><p>Final guidance publication</p></td></tr><tr><td><p>Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [TA357]</p></td><td><p>October 2015</p></td></tr><tr><td><p>Melanoma (unresectable, metastatic, ipilimumab naive) - pembrolizumab [TA366]</p></td><td><p>November 2015</p></td></tr><tr><td><p>Multiple myeloma – panobinostat (post 1 prior therapy) [TA380]</p></td><td><p>January 2016</p></td></tr><tr><td><p>Melanoma (advanced, unresectable, metastatic) - nivolumab [TA384]</p></td><td><p>February 2016</p></td></tr></tbody></table><p><strong> </strong></p><p>NHS England has advised that it envisages, under the new arrangements for the Cancer Drugs Fund (CDF), that a greater number of cancer drugs will be funded from baseline commissioning. Under the new process, any drugs that receive either a draft recommendation for routine commissioning or, where uncertainty exists, a recommendation for use within the CDF, will receive interim funding from the CDF from the point of marketing authorisation.</p><p> </p><p>NICE has advised that it is unable to provide a forecast as to when this will occur for technology appraisals published during the first year of the new CDF as this will depend on a number of factors including the value proposition put forward by manufacturers.</p><p> </p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 07/03/2016 13:36:56 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3396 label Biography information for Lord Clement-Jones

454673

	registered interest
	date	24/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government how many cancer medicines are expected to be given a conditional approval by the National Institute for Health and Care Excellence in the first year of operation of the Cancer Drugs Fund.
	tabling member printed	Lord Clement-Jones
	uin	HL6423
	answer	answer is ministerial correction date of answer 03/03/2016 answer text <p>The National Institute for Health and Care Excellence has advised that it is unable to provide a forecast as the number of technology appraisals published during the first year of the new Cancer Drugs Fund (CDF) will depend on a number of factors including the value proposition put forward by manufacturers.</p><p> </p><p>NHS England has advised that it envisages, under the new arrangements for the CDF, that a greater number of cancer drugs will be funded from baseline commissioning. This will be as a consequence of more appropriate pricing arrangements proposed by pharmaceutical manufacturers and better evidence being available through the Fund as to longer term patient outcomes.</p> answering member printed Lord Prior of Brampton question first answered 03/03/2016 12:51:26 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3396 label Biography information for Lord Clement-Jones

454674

	registered interest
	date	24/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, under the new Cancer Drugs Fund, what steps will be taken to secure early patient access to cancer medicines with Promising Innovative Medicines designation that have successfully passed through the Medicines and Healthcare products Regulation Agency's Early Access to Medicines Scheme.
	tabling member printed	Lord Clement-Jones
	uin	HL6424
	answer	answer is ministerial correction date of answer 03/03/2016 answer text <p>NHS England has advised that, under the proposals considered and approved by NHS England’s Board on 25 February 2016, the new Cancer Drugs Fund will provide access at drug launch for drug/indications which have a draft National Institute for Health and Care Excellence recommendation for use including those drugs that have successfully been through the Early Access to Medicines Scheme.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 03/03/2016 12:52:04 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3396 label Biography information for Lord Clement-Jones